Do‐Youn Oh

Research interests

Publications

• Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial

  BMJ · 2024 · https://doi.org/10.1136/bmj-2023-078876

• Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study

  ˜The œLancet. Gastroenterology & hepatology · 2024 · https://doi.org/10.1016/s2468-1253(24)00095-5

• Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study

  The Lancet Oncology · 2023 · https://doi.org/10.1016/s1470-2045(23)00242-5

• Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

  Journal of Clinical Oncology · 2023 · 10.1200/jco.23.02005

• Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer

  NEJM Evidence · 2022 · https://doi.org/10.1056/evidoa2200015

• Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

  The Lancet Oncology · 2022 · https://doi.org/10.1016/s1470-2045(21)00692-6

• Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study

  Annals of Oncology · 2022 · https://doi.org/10.1016/j.annonc.2022.05.519

• A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1.

  Journal of Clinical Oncology · 2022 · https://doi.org/10.1200/jco.2022.40.4_suppl.378

• Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation

  JAMA Oncology · 2021 · https://doi.org/10.1001/jamaoncol.2021.3836

• Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma

  Journal of Clinical Oncology · 2020 · https://doi.org/10.1200/jco.20.00590

• Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

  The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(20)30109-1

• Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

  The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(20)30157-1

• HALO 109-301: A randomized, double-blind, placebo-controlled, phase 3 study of pegvorhyaluronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients (pts) with previously untreated hyaluronan (HA)-high metastatic pancreatic ductal adenocarcinoma (mPDA).

  Journal of Clinical Oncology · 2020 · https://doi.org/10.1200/jco.2020.38.4_suppl.638

• Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1903387

• Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma

  JAMA Oncology · 2019 · https://doi.org/10.1001/jamaoncol.2019.1588

• A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data

  Gastric Cancer · 2019 · https://doi.org/10.1007/s10120-019-01034-7

• Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer

  Annals of Surgery · 2018 · https://doi.org/10.1097/sla.0000000000002705

• Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet · 2017 · https://doi.org/10.1016/s0140-6736(17)31827-5

• Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma

  Journal of Clinical Oncology · 2017 · https://doi.org/10.1200/jco.2017.75.5009

• Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

  The Lancet · 2015 · https://doi.org/10.1016/s0140-6736(15)00817-x

• Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

  New England Journal of Medicine · 2012 · https://doi.org/10.1056/nejmoa1209124

Current projects

No projects listed.